Takeda licensed the product last year from Protagonist Therapeutics. 6. AstraZeneca, Daiichi unblind Enhertu study early as star ADC helps stomach cancer patients live longer AstraZeneca and ...

Credit: SewCreamStudio / Shutterstock. Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful ‘improvement’ in the DESTINY-Gastric04 Phase III trial, ...

India Post GDS Cut Off: India Post has announced the Gramin Dak Sevak (GDS) Recruitment 2025 under Schedule-I, January 2025, with 21,413 vacancies. The application process concludes today, March 3 ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer ...

Today, March 3, is the last date to apply for the recruitment of Gramin Dak Sevaks (GDS) in different offices of the Department of Posts. Eligible candidates can apply for the posts at ...

(Alliance News) - AstraZeneca PLC on Friday said its breast cancer therapy, Enhertu, which is being developed jointly with Tokyo-based pharmaceutical company Daiichi Sankyo Co Ltd, has been ...

The second poster evaluated the combination of onvansertib and ENHERTU in drug-resistant HR-positive breast cancer PDX models. The combination of onvansertib plus ENHERTU was well tolerated ...

TOKYO & MUNICH - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LON:AZN) (LSE/STO/Nasdaq: NASDAQ:AZN) have announced that their drug ENHERTU (trastuzumab deruxtecan) has been recommended for approval in ...

In a visit to Defence Colony to inspect ongoing infrastructure projects, PWD Minister Parvesh Sahib Singh Thursday reviewed a damaged puliya (small bridge) that has been in disrepair for the last two ...

TOKYO & MUNICH - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: NASDAQ:AZN) have announced that their drug ENHERTU (trastuzumab deruxtecan) has been recommended for approval in the ...